<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25186085</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1749-0774</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Human cell</Title>
                <ISOAbbreviation>Hum. Cell</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>44-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13577-014-0101-3</ELocationID>
            <Abstract>
                <AbstractText>High MET expression in renal cell carcinoma (RCC) and MET activation in bone metastases are reportedly important in progression of several cancers. To find new treatment targets in bone metastasis, we immunohistochemically analyzed expression levels of MET and matriptase (specific cellular activator of hepatocyte growth factor). We obtained nephrectomy specimens from 17 RCC patients with metastasis, and bone metastases specimens from 7 RCC patients who underwent metastasectomies, and who were treated at our hospital between 2008 and 2012. We tested the samples with anti-human MET polyclonal antibody and anti-human matriptase polyclonal antibody, and compared postoperative overall survival (OS) rates between positive and negative groups. High MET expression was seen at primary sites in 8/17 (47%) nephrectomy specimens, and 6/7 (86%) bone specimens. Matriptase was expressed in 6/17 (35%) nephrectomy specimens, and all 7 (100%) bone specimens. Interestingly, matriptase was strongly expressed in osteoclasts of 5/7 bone specimens. Postoperative OS rate was significantly higher in the MET(-) group than the MET(+) group. The high MET and matriptase expression seen in RCC cells in bone metastasis accompanied by matriptase expression in osteoclasts indicates their importance in bone metastasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mukai</LastName>
                    <ForeName>Shoichiro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan, syoichiro_mukai@med.miyazaki-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yorita</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawagoe</LastName>
                    <ForeName>Yukari</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katayama</LastName>
                    <ForeName>Yuichi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakahara</LastName>
                    <ForeName>Kozue</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamibeppu</LastName>
                    <ForeName>Toyoharu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugie</LastName>
                    <ForeName>Satoru</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tukino</LastName>
                    <ForeName>Hiromasa</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamoto</LastName>
                    <ForeName>Toshiyuki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kataoka</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Hum Cell</MedlineTA>
            <NlmUniqueID>8912329</NlmUniqueID>
            <ISSNLinking>0914-7470</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C491743">MET protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.-</RegistryNumber>
                <NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.-</RegistryNumber>
                <NameOfSubstance UI="C485595">matriptase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019859" MajorTopicYN="N">Proto-Oncogene Proteins c-met</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25186085</ArticleId>
            <ArticleId IdType="doi">10.1007/s13577-014-0101-3</ArticleId>
            <ArticleId IdType="pmc">PMC4286132</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Biochem Cell Biol. 2008;40(6-7):1297-316</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18191610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2010 Mar;2(2):75-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21789128</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Surg Pathol. 2006 Jan;14(1):65-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16501837</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Drug Targets. 2010 Sep;11(9):1157-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20545605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Aug 15;12(16):4876-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16914575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Urol. 2002 Aug;168(2):774-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12131367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2012 Aug;10(8):1087-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22689130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 1997 May;16(1):68-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9140397</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013;8(11):e79101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24260160</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5771-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17389401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Physiol. 2012 Apr;227(4):1604-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21678412</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2011 Oct;102(10):1904-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21733044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2011 Apr;22(4):794-800</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20937648</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2014 Jun;11(6):335-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24821212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2012 Jan;11(1):214-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22027690</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bone. 2012 Mar;50(3):704-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22173052</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):223-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12784998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Mol Genet. 1994 Dec;3(12):2169-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7881415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Urology. 2002 Dec;60(6):1113-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12475693</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19496715</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Aug;25(8):1603-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24827131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2007 Apr;98(4):491-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17309599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17456594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Med. 2006 Jan-Mar;12(1-3):1-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16838070</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>